Karyopharm publishes preclinical data in Nature demonstrating Selinexor's potential
Karyopharm announced that preclinical data describing XPO1 inhibition with selinexor, the Company's lead, oral Selective Inhibitor of Nuclear Export / SINE™ compound, in a KRAS-mutant non-small cell lung cancer model, were published online in Nature. September 29, 2016